Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 712
- 主要终点
- Evidence of withdrawal
研究概览
简要总结
The investigators' clinical practice makes use of oral clonidine as a means of transitioning from intravenous dexmedetomidine following prolonged infusions (more than 3-5 days). Although this is common clinical practice, there is limited clinical data to demonstrate the efficacy of this technique and to provide clonidine dosing guidelines. The purpose of this study is to retrospectively review the investigators' experience with the use of oral clonidine to prevent withdrawal following the prolonged administration of dexmedetomidine.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who received clonidine during the transition from dexmedetomidine.
排除标准
- 未提供
研究组 & 干预措施
Clonidine
Patients who received clonidine following prolonged dexmedetomidine infusions
干预措施: Clonidine (Drug)
结局指标
主要结局
Evidence of withdrawal
时间窗: Twice a day from the first day of taper of dexmedetomidine until 72 hrs. after the last dose
Withdrawal is assessed using the Withdrawal Assessment Tool-1 (WAT-1). The 19-item assessment consists of (1) a review of the patient's record for the past 12 hours, (2) direct observation of the patient for 2 minutes, (3) patient assessment during a progressive stimulated exam routinely performed to assess level of consciousness at the beginning of each 12-hour shift, and finally (4) assessment of post-stimulus recovery.
次要结局
未报告次要终点
研究者
Joseph D. Tobias
Chairman, Dept. of Anesthesiology & Pain Medicine
Nationwide Children's Hospital